Nirmatrelvir

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, peptidomimetic inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), with potential antiviral activity against SARS-CoV-2 and other coronaviruses. Upon oral administration, nirmatrelvir selectively targets, binds to, and inhibits the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins, thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease and exoribonuclease. This prevents viral transcription and replication.

**Synonyms:** - NIRMATRELVIR - PF 07321332 - PF-07321332 - PF07321332 - SARS-CoV-2 3CLpro Inhibitor PF-07321332 - SARS-CoV-2-3CL Protease Inhibitor PF-07321332